We have described recently that anti-CD44s, anti-CD44v6 and anti-CD44v7 interfere with delayedtype hypersensitivity (DTH) reactions. Yet, TNBS-induced colitis can be cured only by anti-CD44v7. To clarify the mechanisms underlying the divergent functional activities of CD44v6 and CD44v7 we explored their contribution to lymphocyte activation in vivo and in vitro. 
Introduction
CD44 comprises a set of transmembrane glycoproteins, tion of CD44v6 (24) (25) (26) (27) and delayed-type hypersensitivity (DTH) reactions can be mitigated by anti-CD44v6, but also whose members differ by glycosylation (1), and by insertion of up to 10 variant exons between exon 5 and exon 6 of the by anti-CD44v7 (28, 29) . On the other hand, a severe pancolitis can be prevented and cured only by anti-CD44v7, while CD44 standard isoform (CD44s) (2). Considering functions of CD44 on hematopoietic cells, CD44s has been described as anti-CD44v6 exerts no effect at all (30) . Interestingly, only peripheral blood lymphocytes of patients with a systemic a lymphocyte homing receptor (3-5). In addition, the molecule is involved in lymphocyte maturation (6-11), traffic (12) (13) (14) (15) autoimmune disease display increased levels of CD44v7, whereas elevated levels of CD44v6 were noted in peripheral and activation (16) (17) (18) (19) (20) (21) (22) (23) . Knowledge of functional activity of CD44 variant isoforms v6 and v7 is still scarce. Lymphocyte blood lymphocytes of patients with infectious, allergic as well as autoimmune diseases (31) . activation has been shown to be accompanied by up-regula-The finding that anti-CD44v6 and anti-CD44v7 mitigated a out. Ears were split and put with the inner face down in 1% trypsin for 3 times 20 min at 37°C. LN and spleen were T h 1-induced DTH reaction, but only anti-CD44v7 interfered with a T h 1-mediated gut-associated chronic inflammatory meshed through fine gauze. Subpopulations of lymphocytes were enriched by panning on anti-mouse IgM-coated plates process was unexpected and prompted us to explore whether functional activities of these CD44 isoforms differ principally.
(33). The non-adherent population was defined as T cell enriched and the adherent population as B cell enriched. To We approached the question by antibody blocking studies in vitro and in vivo. Functional activity was evaluated with separate CD4 ϩ and CD8 ϩ cells, the T cell-enriched population was incubated with anti-CD4 or anti-CD8. After washing, cells respect to co-stimulatory activity, modulation of activation markers and cytokine secretion. Although both CD44v6 and were seeded on anti-rat IgG-coated plates. The adherent cells were collected after 2 h of incubation. CD44v7 are involved in the process of lymphocyte activation, our results demonstrate that these CD44 isoforms display Mitogenic and antigenic stimulation was performed with 7.5 µg/ml concanavalin A (Con A), 25 µg/ml lipopolydistinct modes of action. CD44v6 functions as a co-stimulatory molecule predominantly on T cells. CD44v7 rather appears saccharide (LPS), 100 µg/ml DNP-ovalbumin (OVA) or with DNFB haptenized syngeneic lymphocytes. Cells were to be a ligand for co-stimulatory molecules.
cultured for 1-3 days. Thereafter, surface markers and cytokine production were determined. Alternatively, 10 µCi/ml Methods [ 3 H]thymidine was added for the last 16 h of culture. Cells were harvested with an automatic harvester and thymidine Mice and treatment incorporation was determined in a β-counter.
[ 3 H]Thymidine BALB/c mice were obtained from Wiga (Sulzfeld, Germany).
incorporation is presented as proliferation index, whereby They were kept under specific pathogen-free conditions and [ 3 H]thymidine incorporation in the presence of control (mouse were fed sterilized food and tap water ad libitum. Animals and/or rat) IgG has arbitrarily been taken as 1.0 were used for experiments at the age of 8 weeks. Contact
ELISAspot assay (34) allergy was induced by painting 20 µl of 0.5% 2,4-dintro-1-fluorobenzene (DNFB) in 4:1 acetone:olive oil on the rear
Plates were coated with anti-IL-2, anti-IL-4, anti-IL-10, antifootpads of mice for a successive 2 days. Four days later, IFN-γ and anti-TNF-α in bicarbonate buffer, pH 8.9. Plates mice were challenged by painting 10 µl of 0.2% DNFB to were washed and blocked with 100 µg/ml BSA. Cells were each side of both ears (32). Concomitantly with painting, mice added to the coated plates. Plates were incubated for 18-24 received either rat IgG or anti-CD44s or anti-CD44v6 or antih at 37°C, cells were lysed, plates were washed 3 times and CD44v7 (200 µg/100 µl PBS), i.v. Ear thickness was measured 50 µl biotinylated antibody was added for overnight at 4°C. 0, 24, 48 and 72 h after challenge.
After four washings, the enzyme streptavidin-alkaline phosphatase was added in PBS-gelatin-Tween 20. Plates were mAb incubated for 45 min at 37°C. Thereafter they were washed The following mAb were used: anti-CD44s (IM-7, rIgG2b), 5 times before adding the substrate in 1% agar. Spots were anti-CD44v6 (11A6, rIgG2a; Schmidt et al., manuscript in counted after incubation at 37°C for 4 h. preparation), LN7.2 (anti-CD44v7, mIgG2a) (30, Wittig et al.,  Statistics submitted), anti-IFN-γ (R4-6A2, anti-rIgG1), anti-µ (331.12, rIgG2b), anti-CD3 (145-2C11, hIgG), anti-CD4 (YTA3.2.1, Significance of differences were calculated by the two-tailed rIgG2b), anti-CD8 (YTS169.4.1, rIgG2b), anti-Mac-1 Student's t-test. (YBM6.1.1, rIgG2a), anti-IL-2R (7D4, rIgM) and anti-ICAM-1 (YN1/1.7.4, rIgG2a). Culture supernatants were purified by Results passage over Protein G-Sepharose and mAb were used in vitro at a concentration of 10 µg/ml. Anti-CD40, anti-CD40L, Expression profile of CD44v6 and CD44v7 on lymph node cells anti-B7-1, anti-B7-2, anti-CD28, anti-CTLA-4, and pairs of anti-IL-2, anti-IL-4, anti-IL-10, anti-IL-12, anti-IFN-γ and anti-tumor CD44v6 and CD44v7 are not expressed on resting LNC, but necrosis factor (TNF)-α were obtained commercially (Pharbecome transiently up-regulated during lymphocyte activaMingen, Hamburg, Germany). For flow cytometry, FITC-and tion, although with different time kinetics. CD44v6 is predomiphycoerythrin (PE)-labeled isotype-specific secondary antinantly detected on lymphoblasts; expression of CD44v7 is bodies were used. For FACS analysis 3-5ϫ10 5 cells were strongest prior to blast transformation. In comparison to stained according to routine procedures. When assaying CD44s, the intensity of CD44v6 and CD44v7 expression is cytokine-producing cells, lymphocytes were fixed and permeweak (28) . As revealed by fluorescence analysis of subpopulaabilized in advance. As far as they had been stimulated tions of activated leukocytes (Table 1) and double fluoresin vitro, 5 µM monensin was added to the culture medium cence analysis (Fig. 1) , CD44v6 is mainly expressed on T during the last 8 h of culture. Fluorescence was determined cell blasts, whereas CD44v7 is expressed by CD4 ϩ cells, B with an Epics XL (Coulter, Krefeld, Germany) or a FACSCalibur cells and monocytes. (Becton Dickinson, Heidelberg, Germany).
Blocking of lymphocyte activation in vitro by anti-CD44v6 and anti-CD44v7 Lymphocyte preparation and activation
Ears, draining lymph nodes (drLN) and the spleen were Because CD44v6 and CD44v7 are hardly expressed on resting lymphocytes, it could be assumed that these molecexcised, and peritoneal exudate cells (PEC) were washed subsets by CD44 isoform-specific antibodies or be due to an effect of anti-CD44 antibodies on leukocyte migration and/or a BALB/c mice were sensitized with DNFB as described in Methods, recruitment. Anti-CD44s is known to intervene with leukocyte drLNC were collected after 5 days. Leukocyte subpopulations were enriched as described in Methods, cells were kept in culture for activation as well as migration (15, 19) . Since anti-CD44v6 12 h. Expression of CD44 was determined by flow cytometry.
and anti-CD44v7 do not influence adhesion to hyaluronan (data not shown), we hypothesized that these antibodies may preferentially interfere with leukocyte activation.
Impact of anti-CD44 on cytokine production ules are functionally active during lymphocyte stimulation. Therefore, we first evaluated whether anti-CD44v6 and antiTo support the hypothesis that anti-CD44v6 and anti-CD44v7 CD44v7 interfere with lymphocyte proliferation (Fig. 2) . Addiselectively inhibit the activation of leukocyte subsets, cytokine tion of anti-CD44 to the culture medium, indeed, resulted in expression was evaluated in unseparated leukocyte populaa blockade of the proliferative response of spleen cells tions as well as in defined subpopulations and in mixtures (SC) towards the nominal antigen DNP-OVA. Although the of subpopulations. Cytokine (IL-2, IFN-γ, IL-12 and TNF-α) mitogenic response of SC to Con A and LPS was hardly expression was determined by flow cytometry, cytokine secreinfluenced by the anti-CD44v antibodies, anti-CD44s as well tion by ELISAspot and cytokine production by ELISA. as anti-CD44v6 and anti-CD44v7 inhibited the response of B
In the first setting, LNC from untreated donors were stimucell-depleted SC towards Con A. Anti-CD44s and antilated in vitro by DNP-OVA in the presence of CD44-specific CD44v7, but not anti-CD44v6, also inhibited the LPS response antibodies and the percentage of cytokine-expressing cells of T cell depleted SC.
was evaluated in comparison to cultures containing control The anti-CD44 treatment also exerted some effect on the IgG (Fig. 4A) . The strongest reduction in cytokine expression expression of co-stimulatory molecules or their ligands (Table  was seen with anti-CD44s, which inhibited the expression of 2), e.g. expression of the IL-2R, of CD40 and of B7-1 all four cytokines. Anti-CD44v6, instead, interfered exclusively and B7-2 was reduced in anti-CD44s-treated cultures; antiwith IL-2 and IFN-γ expression. Anti-CD44v7 efficiently moduCD44v6 treatment led to a reduction in IL-2R expression; lated TNF-α, IL-12 and IFN-γ expression, but had no effect on in the presence of anti-CD44v7 expression of CD40L was IL-2. The finding that anti-CD44v7 more efficiently hampered significantly lower than in control cultures.
expression of the proinflammatory cytokines IL-12 and TNF-α These findings provided a first hint that anti-CD44v6 might points towards CD44v7 being functionally active at the antidisplay functional activity at the T cell level, while anti-CD44s gen-presenting cell rather than the T cell level. and anti-CD44v7 might function both at the T cell and at the The interpretation was strengthened by the analysis of B cell level.
cytokine expression in drLNC after sensitization with DNFB under concomitant treatment with CD44-specific antibodies Anti-CD44v6 and anti-CD44v7 mitigate a DNFB-mediated ( Fig. 4B) , and in the state of hyper-reactivity in DNFB sensitized DTH reaction and challenged mice ( Fig. 4C-E ). In the in vivo situation, too, anti-CD44s and anti-CD44v6 exerted a strong effect on IFN-γ BALB/c mice were sensitized and challenged by painting with DNFB in an oil:acetone mix. Mice concomitantly received expression. Anti-CD44v7 again modulated preferentially IL-12 expression and, possibly as a consequence thereof, IFN-γ i.v. injections of anti-CD44 antibodies. As has been reported, treatment with anti-CD44s strongly reduced edema formation expression. TNF-α expression was reduced in sensitized mice, yet was unaltered in the state of hyper-reactivity. Treatand retarded the infiltration of leukocytes (13,35). Anti-CD44v6 and anti-CD44v7 had less effect on edema formation (28) ment with anti-CD44v6 and anti-CD44v7 exerted similar effects on leukocytes infiltrating the ear as described for (Fig. 3A) . However, a significantly reduced number of leukocytes was recovered from the injured ear ( Fig. 3B ) and the drLNC. Instead, the effect of anti-CD44s on cytokine expression by infiltrated cells was less impressive (Fig. 4D ). As expansion of lymphocytes in the drLN was slightly impaired (Fig. 3C ). Furthermore, after sensitization and challenge with shown for drLNC, cytokine secretion did not differ significantly from the pattern of cytokine expression (Fig. 4E ). This also DNFB, control mice frequently appeared rather exhausted with weight loss, fever and fatigue. Occasionally local accounted for cytokine production as determined by ELISA (data not shown). Schwartzmann reactions were noted (data not shown) and beyond 3 days after the challenge drLN frequently were Thus, anti-CD44s, anti-CD44v6 and anti-CD44v7 efficiently interfered with cytokine expression, production and secretion, emaciated. Because wasting symptoms were only seen in animals not receiving anti-CD44, it is obvious that the antibut the three antibodies differed with respect to the predomi- LNC were stained with biotinylated anti-CD44v6 and anti-CD44v7, and counterstained with streptavidin-PE. A single parameter overlay is shown. White area, negative control; grey area, anti-CD44v7; black area, anti-CD44v6. (B) LNC were cultured in the presence of Con A (7.5 µg/ml), and SC as well as PEC in the presence of LPS (25 µg/ml). LNC were stained with anti-CD4 or anti-CD8, SC with anti-µ and PEC with anti-CD11b as first antibody and FITC-labeled anti-rat IgG as second antibody (x-axis). All probes were stained with either biotinylated anti-CD44v6 or anti-CD44v7 and were counterstained with streptavidin-PE (y-axis). The negative control has been treated with rat IgG as control for the first antibody, FITC-labeled anti-rat IgG and streptavidin-PE. The population of large cells (LNC and SC) and of large and more granulated cells (PEC) has been gated. Anti-CD44v6 preferentially stained T cells and a fraction of monocytes; anti-CD44v7 stained part of CD4 ϩ cells, B cells and monocytes. nantly blocked cytokine. Furthermore, in a pathological state cells and monocytes. The separated populations were maintained in culture for 24 h in the presence of antiof hyper-reactivity, the effect of anti-CD44s was stronger in drLNC than locally, whereas in anti-CD44v6-and antiCD44v6 or anti-CD44v7 and tested for cytokine expression (Fig. 5A ). Treatment with anti-CD44v6 influenced IL-2 and CD44v7-treated mice similar effects were observed on infiltrated cells and drLNC. We interpreted the findings in IFN-γ expression by CD4 ϩ and CD8 ϩ cells. Besides, TNF-α expression by monocytes was reduced. The cytokine the sense that (i) CD44s, but not CD44v6 and CD44v7, influenced leukocyte migration, and (ii) anti-CD44s, antiexpression profile was different in the presence of antiCD44v7. The antibody had no influence on cytokine CD44v6 and anti-CD44v7 interfered with different leukocyte subsets.
expression by CD8 ϩ cells. However, cytokine expression by CD4 ϩ cells, B cells and monocytes was altered in the Anti-CD44v6, but not anti-CD44v7, directly blocks cytokine presence of anti-CD44v7. Notably, the influence of antiexpression by T cells.
CD44v7 on cytokine expression by these leukocyte subpopulations was not uniform: expression of IFN-γ by CD4 ϩ To answer the question whether anti-CD44v6 and antiCD44v7 directly block the activation of defined leukocyte cells and monocytes was decreased; the percentage of monocytes producing TNF-α also was decreased and fewer subsets or interfere with a cell-cell interaction, drLNC from DNFB sensitized BALB/c mice, which had received either B cells expressed IL-12. On the other hand, the number of monocytes expressing IL-12 was slightly increased. As control IgG or anti-CD44v6 or anti-CD44v7, were separated into populations enriched for CD4 ϩ cells, CD8 ϩ cells, B evaluated by ELISAspot and ELISA, cytokine expression corresponded to cytokine secretion (Fig. 5B ) and cytokine production (data not shown). Thus, anti-CD44v6 and anti- a Draining LNC and PEC were collected from DNFB-sensitized plus antibody-treated mice. Leukocyte subpopulations were enriched as described in Methods. Leukocyte subpopulations or mixtures of leukocyte subpopulations were maintained in culture for 24 h. CD4 ϩ cells were cultured separately (Table 4B and Fig. 6 ).
anti-CD44v7-treated mice. To answer the question, B cells or CD4 ϩ cells were cultured with monocytes from untreated, When B cells were cultured with monocytes in the presence of anti-CD44v7, TNF-α production was reduced and IL-12 DNFB-treated and DNFB plus anti-CD44v7-treated mice collecting only the non-adherent cells for the determination of production was more strongly reduced than in cultures containing only B cells (Table 4B) . With respect to the decreased cytokine expression (Fig. 7) . When B cells were cultured with monocytes from untreated expression of IL-12 by CD4 ϩ cells and B cells which have been cultured with monocytes in the presence of anti-CD44v7 or DNFB-treated mice, TNF-α and IL-12 expression was unaltered or increased. Instead, when monocytes were it should be remembered (Fig. 5) that expression of IL-12 in monocytes was up-regulated by anti-CD44v7.
derived from DNFB plus anti-CD44v7-treated mice, less B cells expressed IL-12 and TNF-α. This was independent of These findings gave an independent confirmation of our hypothesis that the distinct effects of anti-CD44v6 and antithe activation state of the B cells, i.e. it was seen with B cells from untreated and DNFB-sensitized mice. The effect was CD44v7 are due to the involvement of different leukocyte subpopulations. Besides, the partly opposing effects of antialso independent on whether or not the B cells had already been in contact with anti-CD44v7 (Fig. 7A) . From this experiCD44v7 on enriched populations of CD4 ϩ cells, B cells and monocytes versus mixtures of these populations supported ment it becomes apparent that anti-CD44v7 blocked an interaction between monocytes and B cells which normally the idea that anti-CD44v7 may affect not only the CD44v7 receptor bearing cell but, in addition and by preventing an stimulates IL-12 and TNF-α production by the B cells. Since a purified population of B cells from DNFB and anti-CD44v7-interaction with the so far undefined ligand, the ligand bearing population. treated mice produced high levels of IL-12 and TNF-α, it must be the monocyte which is directly affected by anti-CD44v7.
Anti-CD44v7 apparently interferes with signaling from sensit-
Yet, the effect becomes apparent at the (ligand bearing) B cell.
ized monocytes towards B cells and T h cells
Since IL-10 and IL-12 have been described to be of mutual counteracting influence, we finally evaluated IL-10 expression If the latter hypothesis holds true and CD44v7 functions as a receptor on monocytes for a ligand expressed by CD4 ϩ cells in co-cultures of B cells or CD4 ϩ cells with monocytes (Fig.  7B) . IL-10 expression in B cells was strongly reduced in the and B cells, CD4 ϩ cells and B cells should respond differently to monocytes from DNFB-versus monocytes from DNFB plus presence of monocytes from DNFB-treated as compared to monocytes from untreated mice. In the presence of monocytes in DNFB plus anti-CD44v7-treated mice ( Fig. 7A and B) .
Whether the up-regulation of IL-10 expression by CD4 ϩ cells from DNFB plus anti-CD44v7-treated mice, IL-10 expression by B cells was restored. Also, a higher percentage of CD4 ϩ and by B cells is a consequence of the reduced expression of IL-12 and TNF-α or is an independent phenomenon will be cells expressed IL-10 when cultured with monocytes from DNFB plus anti-CD44v7-treated mice. The phenomenon, discussed. again, was independent of whether or not the B cell and the CD4 ϩ cell had been in contact with anti-CD44v7. Thus, the Discussion experiment confirms that CD4 ϩ cells and B cells are released from suppression to produce IL-10 by blocking CD44v7 on Several other groups and ourselves have described the involvement of CD44v6 in lymphocyte activation (24) (25) (26) (27) . In monocytes. Finally, it should be noted that the percentage of IL-10-expressing B cells as well as CD4 ϩ cells was increased view of this evidence we were surprised to notice that anti-CD44v6 treatment was ineffective in a TNBS-induced colitis, ligand. In vitro as well as in vivo, production and secretion of IL-2 and IFN-γ are impaired in the presence of anti-CD44v6, while a complete cure could be achieved with anti-CD44v7 (30) . The divergent effects of anti-CD44v6 and anti-CD44v7 while expression of the proinflammatory cytokine IL-12 is unimpaired. The reduced production of TNF-α by monocytes were not restricted to the mucosa-associated immune system, e.g. anti-CD44v6 and anti-CD44v7, like anti-CD44s, also could be a consequence of the reduced amount of IFN-γ, which is known to stimulate TNF-α production by monocytes. mitigated a T h 1-mediated DTH reaction. Yet, anti-CD44v6 exerted only a minor effect on a FITC-induced, supposedly
In addition, a reduced number of CD8 ϩ cells has been recovered from the infiltrate in DNFB-painted mice. These T h 2-mediated DTH reaction (28) . To attain further hints as to the cause of the distinct effects of anti-CD44v6 and antifindings are in line with the interpretation that CD44v6 is predominantly involved in the activation of cytolytic T cells. CD44v7 we evaluated the influence of these two antibodies on leukocyte activation and cytokine expression in a DNFBSo far, we do not know the signals triggered by CD44v6 ligation.
Irrespective of this open question, the data demoninduced DTH reaction. Our data support the idea that the distinct activities of CD44v6 and CD44v7 are due to different strate that the functional principle of CD44v6 differs from that of CD44s. Whereas CD44s-CD44s ligand interactions can expression patterns. In addition, blocking of CD44v7 does not only alter functional activity of the CD44v7 receptor initiate signaling in both the CD44s and the CD44s ligandbearing cells (19, 21, 37, 38) , occupancy of CD44v6 by the bearing cell, but also has bearing on cells expressing a so far undefined CD44v7 ligand.
antibody apparently influenced only the CD44v6-expressing T cell. Interestingly, a recent report described that priming of Though the main objective of our study was a definition of functional differences between CD44v6 and CD44v7, we CD8 ϩ cells in DTH reactions occurs independently of priming of CD4 ϩ cells (45). The finding that anti-CD44v6 interfered briefly want to comment on the effects mediated by antiCD44s. There are numerous reports claiming that CD44s can predominantly with the CD8 ϩ population could well explain that anti-CD44v6 mitigated a DNFB-induced, but not a T H 2-function as a co-stimulatory receptor (19, 21, 37) as well as a ligand for a co-stimulatory molecule (38) in lymphocyte mediated FITC-induced DTH reaction (28) and that it failed to modulate a T h 1-mediated TNBS induced colitis (30) . activation. In addition, there are reports on the involvement of CD44s in DTH reactions (13, 28, 29, 35, 39) , i.e. blockade of Expression of CD44v7 differs from expression of CD44v6, i.e. CD44v7 is expressed on small subpopulations of activated a CD44-hyaluronic acid interaction by anti-CD44s inhibits the migration of monocytes into and within the site of inflammation CD4 ϩ cells, B cells and monocytes. Similar to anti-CD44v6, anti-CD44v7 mitigated a T h 1-mediated DTH reaction. When (39) . Furthermore, it has been described before in an elegant study by Grendele et al. (15) that CD44s plays an important lymphocytes were stimulated in the presence of anti-CD44v7, expression of CD40 ligand and occasionally (data not shown) role in leukocyte extravasation. The relative reduction of monocytes seen in the infiltrate of anti-CD44s-treated mice is of CD40 was reduced. Anti-CD44v7-induced changes in cytokine expression were rather complex in that a strong in line with these studies. In addition, the most strongly reduced edema formation in anti-CD44s-treated mice may decrease in the proinflammatory cytokine IL-12 and a less impressive reduction of IFN-γ was observed, while expression be a consequence of the impaired activation of monocytes and a reduction in monocyte-derived mediators. Finally, we of IL-2 was unaltered. The effect was seen in the drLN as well as in infiltrated cells, the infiltrate containing a significantly want to comment on the fact that the number of leukocytes in the injured organ has been reduced, but cytokine expresreduced number of CD4 ϩ cells. An analysis of cytokine expression by leukocyte subpopulations revealed that subposion by the infiltrated cells has been unimpaired. This finding, too, supports the interpretation that anti-CD44s interferes pulations responded differently to anti-CD44v7. Two observations need particular attention. directly with the process of leukocyte emigration, i.e. the few emigrating cells are functionally unaltered. Notably, the First, DNFB treatment led to a strong up-regulation of IL-12 expression by monocytes. B cells cultured with monocytes phenomenon has not been seen in anti-CD44v6 and antiCD44v7-treated mice, where lymphocytes in the draining from DNFB-treated mice also produced increased levels of TNF-α and IL-12. Anti-CD44v7 did not prevent up-regulation node and in the infiltrate displayed concordant activity profiles. Thus, these CD44 isoforms may not contribute to leukocyte of IL-12 expression by monocytes. However, B cells which had been cultured together with monocytes in the presence emigration.
CD44v6, originally described as a marker of metastasizing of anti-CD44v7 produced IL-12 and TNF-α at a reduced rate. This implies that anti-CD44v7 blocked monocytes to deliver tumor cells in the rat (40), has soon after its discovery been associated with lymphocyte activation (41) and has been a signal towards B cells which initiates TNF-α and IL-12 production. supposed to be involved in clonal expansion of T cells during antigenic stimulation (24) . The finding that expression of Second, after DNFB plus anti-CD44v7 treatment, B cells and CD4 ϩ cells expressed increased levels of IL-10. When CD44v6 is up-regulated in human autoimmune diseases like glomerulonephritis, diabetes, rheumatoid arthritis and chronic B cells and CD4 ϩ cells had been cultured with monocytes from DNFB-treated mice, they produced strongly reduced inflammatory bowel disease (26, (42) (43) (44) is well in line with an involvement of CD44v6 in lymphocyte activation. levels of IL-10. When monocytes were treated with antiCD44v7, IL-10 production by CD4 ϩ cells and B cells was CD44v6 is predominantly expressed on T cells. Blockade of CD44v6 inhibits T cell proliferation, but has no influence restored or even up-regulated. It has been described recently that a population of CD4 ϩ cell, which is naturally suppressed on B cell proliferation. Anti-CD44v6 has no major influence on the expression of additional co-stimulatory molecules and by IL-12, starts to produce IL-10 upon release of suppression (46) . This IL-10 producing CD4 ϩ cells efficiently down-modutheir ligands like B7-1/B7-2-CD28/CTLA-4 or CD40-CD40 dualistic function, i.e. provides a trigger for B cells and
